Pharmaceuticals

The Pegfilgrastim Biosimilars Market Is Evolving Due To Government Initiatives Catalysts For Growth In The COVID-19 Drug-Associated API

May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Pegfilgrastim Biosimilars Market Be By 2030 Compared To Its 2026 Market Size?

The pegfilgrastim biosimilars market size has experienced significant expansion over recent years. Forecasts indicate it will climb from $1.92 billion in 2025 to $2.04 billion in 2026, progressing at a compound annual growth rate (CAGR) of 6.3%. This past growth is attributable to the elevated cost of originator pegfilgrastim, restricted access to biosimilars, an expanding number of cancer patients, increased chemotherapy procedures, and enhanced understanding of neutropenia management.

The pegfilgrastim biosimilars market size is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $2.65 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. Factors contributing to this growth during the projected period include the introduction of novel biosimilars, a greater uptake in supportive oncology treatments, the enlargement of hospital and retail pharmacy networks, governmental encouragements for biosimilar utilization, and increased funding for stem cell transplantation therapies. Key trends foreseen in this period encompass the growing acceptance of pegfilgrastim biosimilars in supportive cancer care, the broadening of hospital and retail pharmacy distribution channels, an intensified focus on mitigating chemotherapy-induced neutropenia, an increase in hematopoietic and peripheral blood stem cell transplantation applications, and heightened investments in managing chronic and severe congenital neutropenia.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

What Factors Are Contributing To The Growth Of The Pegfilgrastim Biosimilars Market?

The pegfilgrastim biosimilars market is anticipated to be driven by government efforts focused on the development of biosimilars. Governments globally are prioritizing biosimilars due to their cost-effectiveness. The US Food and Drug Administration (FDA) initiated a Biosimilar Action Plan to expand treatment options. The Australian government reinforced its commitment to the Biosimilar Awareness Initiative by granting $5 million to the Generic and Biosimilar Medicines Association. This funding supports increased general biosimilar education and activities that promote the appropriate dispensing, prescription, and utilization of biosimilar medicines. Therefore, these governmental initiatives for biosimilar development contribute to enhanced production and awareness, which in turn bolster the growth of the pegfilgrastim biosimilars market. The growing incidence of cancer is expected to fuel the pegfilgrastim biosimilars market moving forward. Cancer refers to a collection of diseases characterized by the uncontrolled multiplication and spread of abnormal cells. The rising prevalence of cancer is linked to an aging population, as advanced age is the most significant risk factor for developing most cancer types, with the majority of cases occurring in individuals over 65 years old. Pegfilgrastim biosimilars are used to lower the risk of infection in cancer patients undergoing chemotherapy by stimulating white blood cell production. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, reported 354,820 new cancer diagnoses in 2023, averaging 972 per day, which was 8,605 more than in 2022. Thus, the increasing incidence of cancer is a significant driver for the pegfilgrastim biosimilars market.

Which Segments Define The Pegfilgrastim Biosimilars Market Segment Structure?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

3) By Route of Administration: Prefilled Syringes (PFS), On-body Injectors (OBI), Other Routes

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia

What Emerging Trends Are Seen In The Pegfilgrastim Biosimilars Market?

Major companies within the pegfilgrastim biosimilars market are concentrating on technological innovation in biopharmaceuticals, such as developing high-quality biosimilars to offer safe, effective, and readily available alternatives to original biologic therapies for cancer patients. High-quality biosimilars are defined as biologic drugs that closely correspond to the reference product in terms of structure, function, safety, and efficacy. For example, in February 2023, Fresenius Kabi, a Germany-based healthcare company specializing in pharmaceuticals and medical technologies, launched Stimufend, its initial pegfilgrastim biosimilar in the U.S. Stimufend both prevents and treats chemotherapy-induced neutropenia and is supplied as a 6 mg/0.6 mL solution in a single-use pre-filled syringe with a built-in needle guard. By integrating advanced biosimilar development with user-friendly delivery, Stimufend signifies a technological advancement in increasing the accessibility of high-quality biologic therapies.

Who Are The Established Players Within The Pegfilgrastim Biosimilars Market?

Major companies operating in the pegfilgrastim biosimilars market are Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy’s Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech, Alvotech, EirGenix, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

Get The Full Pegfilgrastim Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Which Region Is The Largest In The Pegfilgrastim Biosimilars Market?

North America was the largest region in the pegfilgrastim biosimilars market in 2025. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Pegfilgrastim Biosimilars Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Browse Through More Reports Similar to the Global Pegfilgrastim Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795